


Rationale for Combination Therapy in Endometrial and Cervical Cancer^{1,2}

Access the activity, "Practical Perspectives on Rapid Change in Endometrial and Cervical Cancer Management: Exploring Innovative Therapy in Gynecologic Malignancies," at [PeerView.com/VSK40](https://www.peerview.com/VSK40)

Selected Clinical Trials Assessing Immunotherapy in Advanced/Recurrent Endometrial Cancer³

Phase 2


Immunotherapy + TKI
NCT02501096: KEYNOTE-146

Lenvatinib + Pembrolizumab
 Setting: 2L
 Primary Endpoint: ORR at week 24


Monotherapy Immunotherapy
NCT02715284: GARNET

Dostarlimab
 Setting: 2L
 Primary Endpoints: ORR, DOR

Immunotherapy + TKI
NCT03367741

Cabozantinib + Nivolumab vs Nivolumab
 Setting: 2L
 Primary Endpoint: PFS


Monotherapy Immunotherapy
NCT03668340

Adavosertib
 Setting: 2L (serous carcinosarcoma)
 Primary Endpoints: ORR, PFS

Phase 3



Immunotherapy + Chemotherapy
NCT03981796: RUBY
 Dostarlimab + carboplatin-paclitaxel vs
 placebo + carboplatin-paclitaxel
 Setting: 1L
 Primary Endpoint: PFS



Immunotherapy + Chemotherapy
NCT03603184: AtTEnd
 Atezolizumab + carboplatin-paclitaxel
 vs placebo + carboplatin-paclitaxel
 Setting: 1L
 Primary Endpoints: PFS, OS



**Immunotherapy + Chemotherapy;
 Immunotherapy ± PARP Inhibitor**
NCT04269200: DUO-E
 Durvalumab + carboplatin-paclitaxel,
 followed by durvalumab ± olaparib maintenance
 Setting: 1L
 Primary Endpoint: PFS



Immunotherapy + TKI
NCT03884101: LEAP-001
 Lenvatinib + Pembrolizumab vs
 carboplatin-paclitaxel
 Setting: 1L
 Primary Endpoints: PFS, OS

Immunotherapy + TKI
NCT03517449: KEYNOTE-775
 Lenvatinib + Pembrolizumab vs
 physician's choice chemotherapy
 Setting: 2L
 Primary Endpoints: PFS, OS

Access the activity, "Practical Perspectives on Rapid Change in Endometrial and Cervical Cancer Management: Exploring Innovative Therapy in Gynecologic Malignancies," at **PeerView.com/VSK40**

Selected Clinical Trials Assessing Immunotherapy in Cervical Cancer³

Phase 2

**Monotherapy Immunotherapy**

NCT02628067: KEYNOTE-158

Pembrolizumab

Setting: 2L

Primary Endpoint: ORR

Dual Immunotherapy
 NCT02488759: CheckMate -358
 Nivolumab + Ipilimumab
 Setting: 2L
 Primary Endpoints: ORR, safety

**Immunotherapy + PARP Inhibitor**

NCT04068753: STAR

Dostarlimab + Niraparib

Setting: 2L

Primary Endpoint: ORR

Phase 3

Immunotherapy + Chemotherapy

NCT03635567: KEYNOTE-826

Pembrolizumab + chemotherapy vs
placebo + chemotherapy

Setting: 1L

Primary Endpoints: PFS, OS



Monotherapy Immunotherapy
 NCT03257267: EMPOWER-Cervical 1
 Cemiplimab vs
 investigator's choice chemotherapy
 Setting: 1L
 Primary Endpoint: OS

**Immunotherapy + Chemoradiotherapy**

NCT03830866: CALLA

Durvalumab + SoC CCRT vs
placebo + SoC CCRT

Setting: 1L

Primary Endpoint: PFS

**Chemotherapy + TKI ± Immunotherapy**

NCT03556839: BEAT

cisplatin-paclitaxel + Bevacizumab
± Atezolizumab

Setting: 1L

Primary Endpoint: OS

**Immunotherapy + Chemoradiotherapy**

NCT04221945: KEYNOTE-A18

Pembrolizumab + CRT vs
placebo + CRT

Setting: 1L

Primary Endpoints: PFS, OS

CCRT: concurrent chemoradiotherapy; CTL: cytotoxic T lymphocytes; irAE: immune-related adverse event; PD-1: programmed cell death protein 1; PD-L1: programmed cell death ligand 1; TKI: tyrosine kinase inhibitor.
 1. Wang D et al. *J Hematol Oncol*. 2019;12:42. 2. Makker V et al. 2019 American Society of Clinical Oncology Annual Meeting (ASCO 2019). Abstract TPS5607. 3. <https://clinicaltrials.gov>.

Access the activity, "Practical Perspectives on Rapid Change in Endometrial and Cervical Cancer Management: Exploring Innovative Therapy in Gynecologic Malignancies," at **PeerView.com/VSK40**